Background Stroke prevention treatment guidance for patients with atrial fibrillation (AF)
uses evidence generated from randomised controlled trials (RCTs). However, applicability to …

Warfarin is the standard of care for stroke prevention in patients with atrial fibrillation (AF).
However, it has several drawbacks: it carries a significant risk of bleeding, requires …

Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke
prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of …

Background—Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF)
patients unsuitable for warfarin by 63% but does not increase major bleeding. We sought to …

Atrial fibrillation is an irregular heart rhythm, and it is one of the most common cardiac
arrhythmias. It is associated with a five times increase in the risk of stroke. Anti-coagulants …

Atrial fibrillation (AF) is associated with significant mortality and morbidity, and stroke
represents the most-feared complication. Consequently, AF treatment has focused on …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

Clinical guidelines 1, 2 advocate the use of oral anticoagulation, whether a vitamin K
antagonist (VKA) or one of the novel agents, for stroke prevention in patients with atrial …